JAK2-IN-14
JAK2-IN-14 is an orally active JAK2 inhibitor with an IC50 of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3087335-24-5
- Formule: C26H33N7O
- Masse moléculaire:459.59
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
JAK2 2 nM (IC50) |
JAK1 179 nM (IC50) |
JAK3 161 nM (IC50) |
Tyk2 102 nM (IC50) |
STAT5 |
JAK2-IN-14 (Compound 15au) (0.01-5 μM, 24 h) significantly induces cell cycle arrest at the G2/M phase and cell apoptosis in a dose-dependent manner in BaF3-JAK2V617F and HEL cells[1].
JAK2-IN-14 (0.05-1 μM, 2 h) effectively inhibits the phosphorylation of JAK2 and its downstream signaling molecule STAT5 in BaF3-JAK2V617F and HEL cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BaF3-JAK2V617F and HEL cells
-
Concentration:10, 50, 100, 500 and 1000 nM
-
Incubation Time:24 h
-
Result:Blocked the progression of tumor cells at the G2/M phase, leading to a decrease in the proportions of cells in the G1/G0 and G2 phases.
-
Cell Line:BaF3-JAK2V617F and HEL cells
-
Concentration:10, 50, 100, 500 and 1000 nM
-
Incubation Time:2 h
-
Result:Reduced p-JAK2 and p-STAT5 levels concentration-dependently.
| Species | Dose | Route | Cmax | Tmax | T1/2 | CL/F | AUC0-t |
|---|---|---|---|---|---|---|---|
| Mice[1] | 5 mg/kg | p.o. | 2101.0 ng/mL | 1.0 h | 7.8 h | 1.0 L/h/kg | 5069.7 ng·h/mL |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BaF3-JAK2V617F allogeneic transplantation model established in BALB/c-nude mice[1]
-
Dosage:7.5, 15 and 30 mg/kg
-
Administration:Oral administration (p.o.), once daily for 13 days
-
Result:Demonstrated significant therapeutic efficacy, reducing spleen weight by 24.1%, 26.4%, and 40.5% at doses of 7.5, 15, and 30 mg/kg, respectively
-
Animal Model:HEL cells xenograft model was established in 6-week-old male BALB/c nude mice[1]
-
Dosage:20 and 40 mg/kg
-
Administration:Oral administration (p.o.), once daily for 28 days
-
Result:Significantly inhibited subcutaneous tumor growth.
did not induce observable body weight loss during the experimental period.
Chemical Information
-
CAS No. 3087335-24-5
-
Masse moléculaire 459.59
-
Formule C26H33N7O
-
SMILES
CC1=CN=C(NC2=CC=C(N3CCN(CC4CC4)CC3)C5=C2)N=C1C6=CN(CCCCO5)N=C6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JAK2-IN-14 Related Classifications
HY-175684 Related Classifications
Powered by Bioz